Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
PLoS Negl Trop Dis. 2021 May 20;15(5):e0009383. doi: 10.1371/journal.pntd.0009383. eCollection 2021 May.
Cholera is an acute, diarrheal disease caused by Vibrio cholerae O1 or 139 that is associated with a high global burden.
We analyzed the estimated duration of immunity following cholera infection from available published studies. We searched PubMed and Web of Science for studies of the long-term immunity following cholera infection. We identified 22 eligible studies and categorized them as either observational, challenge, or serological.
We found strong evidence of protection at 3 years after infection in observational and challenge studies. However, serological studies show that elevated humoral markers of potential correlates of protection returned to baseline within 1 year. Additionally, a subclinical cholera infection may confer lower protection than a clinical one, as suggested by 3 studies that found that, albeit with small sample sizes, most participants with a subclinical infection from an initial challenge with cholera had a symptomatic infection when rechallenged with a homologous biotype.
This review underscores the need to elucidate potential differences in the protection provided by clinical and subclinical cholera infections. Further, more studies are warranted to bridge the gap between the correlates of protection and cholera immunity. Understanding the duration of natural immunity to cholera can help guide control strategies and policy.
霍乱是由霍乱弧菌 O1 或 O139 引起的急性腹泻病,在全球造成了沉重负担。
我们分析了现有发表研究中关于霍乱感染后免疫持续时间的估计。我们在 PubMed 和 Web of Science 上搜索了关于霍乱感染后长期免疫的研究。我们确定了 22 项符合条件的研究,并将其分为观察性、挑战或血清学研究。
我们在观察性和挑战研究中发现,感染后 3 年有很强的保护证据。然而,血清学研究表明,潜在保护相关性的体液标志物升高在 1 年内恢复到基线。此外,亚临床霍乱感染可能提供的保护作用低于临床感染,这 3 项研究表明,尽管样本量较小,但初次感染霍乱的亚临床感染的大多数参与者在再次感染同源生物型时出现了有症状的感染。
本综述强调了阐明临床和亚临床霍乱感染提供的保护作用潜在差异的必要性。此外,需要开展更多研究来弥合保护相关性和霍乱免疫之间的差距。了解对霍乱的自然免疫持续时间有助于指导控制策略和政策。